Accelerated Access: Oncology

Improve time, investment, and quality of RWE decision-making with rapid access to RWD from leading oncology data providers

With the ability of real-world evidence (RWE) to inform all phases of the product lifecycle, the availability of oncology real-world data (RWD) is rapidly expanding. While many RWD vendors offer solutions, selecting the right oncology data for your research question can be difficult.  


Accelerated Access: Oncology simplifies the data selection process by providing rapid access to several oncology datasets on our scientifically validated platform, Aetion® Substantiate, and increases the return on your oncology data investments by utilizing Aetion’s oncology expertise and technology to generate RWE.

Blurb about Aetion’s oncology center of excellence page when ready

Maximize the value of your oncology data purchase

Rapid access to oncology real-world datasets

Data from three industry-leading providers of oncology RWD spanning 18 common tumor types is already loaded onto Aetion Evidence Platform® (AEP), reducing the time to access ready-to-analyze data by up to 14 weeks.

Streamlined feasibility assessment

Our experts can conduct quick, unbiased assessments based on our knowledge of the data to determine if your RWE needs can be met by the RWD we have available, increasing confidence in selecting the right dataset and accelerating decision making.

Enhanced value extracted from the data

Our technology and expertise – including 15 senior oncology experts with over 85 years of experience in data selection, study design and execution, and regulatory, with 115+ peer-reviewed oncology publications – increase the value extracted from the data, resulting in more impactful evidence generation. 

“Our clients’ research aims pertaining to oncology often require specialized data fields not available in standard EHR or claims databases. This offering provides our clients with efficient access to three leading sources of rich oncology data, across a variety of cancer types.”


- Ulka Campbell, PhD

Head Of Scientific Strategy, Aetion

Tumor Types:
Bladder cancer
Gastroesophageal cancer
Prostate cancer
Renal cancer
Breast cancer
Colorectal cancer
Ovarian/Uterine cancer
Non-small cell lung cancer
Acute myeloid leukemia (AML)
Chronic lymphocytic leukemia (CLL)
Diffuse large b-cell lymphoma (DLBCL)
Follicular lymphoma (FL)
Mantle cell lymphoma (MCL)
Myelodysplastic syndromes (MDS)
Multiple myeloma (MM)
Marginal zone lymphoma (MZL)


Key Variables:
Performance status
Tumor grade
Progression/relapse & response
Site of metastasis